Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus

Virology

Volumn 251, Issue 1, 1998, Pages 158-164

  Esumi, Mariko ^a   Ahmed, Mamun ^a   Zhou, Yi Hua ^a   Takahashi, Hidenori ^a   Shikata, Toshio ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN ANTIBODY REACTION; ARTICLE; CHRONIC HEPATITIS; CROSS REACTION; EPITOPE MAPPING; HEPATITIS C; HEPATITIS C VIRUS; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; VIRUS REPLICATION;

ANIMALIA; HEPATITIS C VIRUS; MURINAE; RNA VIRUSES;

EID: 0032506108     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9393     Document Type: Article

References (18)

1. Ahmed M., Shikata T., Esumi M. Murine humoral immune response against recombinant structural proteins of hepatitis C virus distinct from those of patients. Microbiol. Immunol. 40:1996;169-176.
2. Choo Q.-L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C., Kansopon J., McFarland J., Tabrizi A., Ching K., Moss B., Cummins L. B., Houghton M., Muchmore E. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA. 91:1994;1294-1298.
3. da Silva Cardoso M., Siemomneit K., Nemecek V., Epple S., Koerner K., Kubanek B. The serology of hepatitis C virus (HCV) infection: Antibody crossreaction in the hypervariable region 1. Arch. Virol. 140:1995;1705-1713.
4. Esumi M., Hayashi N., Takahashi H., Shikata T., Moriyama M., Arakawa Y., Eto T., Nishihara T., Nozaki C., Mizuno K. Immunoreactive core peptides of hepatitis C virus produced inEscherichia coliin vitro. J. Virol. Methods. 59:1996;91-98.
5. Esumi M., Shikata T. Hepatitis C virus and liver diseases. Pathol. Int. 44:1994;85-95.
6. Farci P., Alter H. J., Wong D. C., Miller R. H., Govindarajan S., Engle R., Shapiro M., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediatedin vitro. Proc. Natl. Acad. Sci. USA. 91:1994;7792-7796.
7. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H. J., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA. 93:1996;15394-15399.
8. Hayashi N., Higashi K., Kaminaka K., Sugimoto H., Esumi M., Komatsu K., Hayashi K., Sugitani M., Suzuki K., Okano T., Nozaki C., Mizuno K., Shikata T. Molecular cloning and heterogeneity of the human hepatitis C virus (HCV) genome. J. Hepatol. 17:1993;s94-s104.
9. Hijikata M., Shimizu Y. K., Kato H., Iwamoto A., Shih J. W., Alter H. J., Purcell R. H., Yoshikura H. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J. Virol. 67:1993;1953-1958.
10. Kaito M., Watanabe S., Tsukiyama-Kohara K., Yamaguchi K., Kobayashi Y., Konishi M., Yokoi M., Ishida S., Suzuki S., Kohara M. Hepatitis C virus particle detected by immunoelectron microscopic study. J. Gen. Virol. 75:1994;1755-1760.
11. Kato N., Sekiya H., Ootsuyama Y., Nakazawa T., Hijikata M., Ohkoshi S., Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67:1993;3923-3930.
12. Marchuk D., Drumm M., Saulino A., Collins F. S. Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res. 19:1991.
13. Nishihara T., Nozaki C., Nakatake H., Hoshiko K., Esumi M., Hayashi N., Hino K., Hamada F., Mizuno K., Shikata T. Secretion and purification of hepatitis C virus NS1 glycoprotein produced by recombinant baculovirus-infected insect cells. Gene. 129:1993;207-214.
14. Scarselli E., Cerino A., Esposito G., Silini E., Mondelli M. U., Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J. Virol. 69:1995;4407-4412.
15. Shimizu Y. K., Hijikata M., Iwamoto A., Alter H. J., Purcell R. H., Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68:1994;1494-1500.
16. Shimizu Y. K., Igarashi H., Kiyohara T., Cabezon T., Farci P., Purcell R. H., Yoshikura H. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology. 223:1996;409-412.
17. Thompson J. D., Higgins D. G., Gibson T. J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1994;4673-4680.
18. Weiner A. J., Geysen H. M., Christopherson C., Hall J. E., Mason T. J., Saracco G., Bonino F., Crawford K., Marion C. D., Crawford K. A., Brunetto M., Barr P. J., Miyamura T., McHutchinson J., Houghton M. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA. 89:1992;3468-3472.